<DOC>
	<DOCNO>NCT01986998</DOCNO>
	<brief_summary>The investigator plan carry multicenter randomize clinical trial MRI study high-dose oMP ( 1250mg/day 3 day ) versus lower-high dose oMP ( 625mg/day 3 day ) demonstrate lower-high dose oMP effective higher-high dose oMP acute relapse multiple sclerosis ( MS ) . If show , purpose promote therapeutic regimen safer patient ( less adverse effect ) less costly healthcare system .</brief_summary>
	<brief_title>Study Compare Clinical Radiological Efficacy 625 mg Versus 1250 mg Oral Methylprednisolone Patients With Multiple Sclerosis Relapse</brief_title>
	<detailed_description>DESIGN : Phase IV clinical trial , multicentre , randomize double blind , active drug control parallel group . Patients randomise high dose oMP vs lower-high dose oral Methylprednisolone ( oMP ) . SETTING : 9 MS Units 9 hospital public health system extensive experience treat patient MS design participation clinical trial . PROCEDURES : After sign informed consent , inclusion exclusion criterion specific study check . The diagnostic test take place prior administration study medication include medical history , neurological examination ( EDSS measurement ) take vital sign ( blood pressure , heart rate body temperature ) MRI . Concomitant medication check . Patients instructed requirement study . The trial medication provide patient medical office ( day 1 study ) , patient remain intake . This action repeat follow 2 day . The latency period begin relapse start treatment register . The questionnaire tolerance complete . Day 1 define first day first dose oMP administer . Once give treatment study , adverse event report spontaneously question collect . There follow-up visit 7 28 day , 3 month initiation treatment . At baseline , prior drug administration , day 7 28 initiation treatment , brain MRI without contrast perform . In case adverse event laboratory abnormality , patient could accessory follow-up visit resolution . Randomization perform day administration ( day 1 ) The treatment : Group A : Methylprednisolone 1250 mg / day orally 3 day Group B : Methylprednisolone 625 mg / day orally 3 day</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Relapsingremitting MS ( Mc Donald criterion 2010 ) regardless immunomodulatory treatment 2 . EDSS ( previous relapse ) 0 5 3 . MS relapse moderate intensity ( EDSS increase 1 2.5 point ) severe intensity ( EDSS increase &gt; 3 point ) If EDSS previous relapse available : optic neuritis , myelitis brainstem relapse : EDSS increase 1 point visual , pyramidal brainstem system function relapse location uncertain location : EDSS increase least 1 point If EDSS previous relapse available : optic neuritis , myelitis brainstem relapse : visual , pyramidal brainstem system function &gt; 2 point . relapse location uncertain location : EDSS &gt; 2 point 4 . Recent clinical relapse onset ( &lt; 15 day ) without fever 5 . One month clinical stability prior relapse 6 . Signed informed consent 7 . Capacity ingest medication . 1 . Doubts diagnosis multiple sclerosis 2 . First episode inflammatory neurological disease 3 . Secondary progressive MS primary progressive MS 4 . Symptoms last less 24 hour evolution 5 . Any degree subjective objective remission 6 . Treatment corticosteroids previous 30 day 7 . Patients immunosuppressive treatment ( azathioprine , mitoxantrone , cyclophosphamide ) Natalizumab Fingolimod 8 . Pregnancy breastfeed woman woman childbearing potential use contraceptive measure 9 . Diseases contraindication treatment corticosteroid 10 . History serious adverse reaction hypersensitivity drug relate study medication 11 . Patients could regular MRI , collaborator require anesthesia . 12 . Lactose intolerance 13 . Patients allergy contrast use MRI 14 . Patients renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Multiple sclerosis relapse</keyword>
	<keyword>oral methylprednisolone</keyword>
	<keyword>EDSS</keyword>
	<keyword>gadolinium</keyword>
</DOC>